PTC Therapeutics, Inc. Appoints Shane Kovacs as Chief Financial Officer

PTC Therapeutics, Inc. Appoints Shane Kovacs as Chief Financial Officer


SOUTH PLAINFIELD, N.J., June 3, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Shane Kovacs as Chief Financial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr. Kovacs will be responsible for all finance-related activities at PTC.

"We are excited to welcome Shane as a member of our senior management team," stated Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. "His extensive background in both the finance and biotechnology sectors makes him a valuable addition to PTC."

Prior to joining PTC, Mr. Kovacs served as Managing Director, Health Care Investment Banking at Credit Suisse. In this capacity, he focused on advising life sciences companies on transactions ranging from equity and debt financings to mergers and acquisitions. He joined Credit Suisse in 2004 and held various positions of increasing responsibility. Prior to Credit Suisse, Mr. Kovacs worked in investment banking at National Bank Financial in Toronto. Mr. Kovacs received an MBA from Richard Ivey School of Business at the University of Western Ontario and a Bachelors of Engineering in Chemical Engineering and a Bachelors of Sciences in Life Sciences from Queen's University in Kingston, Ontario. Mr. Kovacs is also a CFA Charterholder.

"I had the pleasure of working closely with PTC's leadership team in my prior role at Credit Suisse," stated Mr. Kovacs. "I am both honored and excited by the opportunity to join Stuart and the entire PTC team as they strive to impact the lives of patients with life-threatening conditions."

About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and are the basis for collaborations with leading biopharmaceutical companies. For more information, visit the company's web site at

SOURCE PTC Therapeutics, Inc.

Suggested Articles

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

Drug companies often face steep challenges when entering new markets for the first time. LianBio is here to help.